Reasons Why Hedge Funds Favor Insulet Corp (PODD)

Group 1 - Insulet Corporation (NASDAQ:PODD) is recognized as one of the top 12 Medical Devices stocks favored by hedge funds, with a highly bullish consensus view from analysts [1] - The stock has received coverage from 18 analysts, resulting in 16 Buy ratings, 1 Hold rating, and only 1 Sell rating, indicating strong market confidence [1] - The consensus 1-year median price target for Insulet is $369.59, suggesting an upside potential of over 43% from its current level [1] Group 2 - Analyst David Roman from Goldman Sachs reaffirmed a Buy rating for Insulet, adjusting the price target from $388 to $365, while still projecting over 41% upside potential [2] - Roman noted that share price movements in 2025 diverged from company fundamentals, but expects valuations to align closely with organic growth prospects in the coming year [2] Group 3 - Insulet Corporation specializes in manufacturing and selling insulin management systems, particularly through its Omnipod platform, which includes a disposable tubeless pump designed for insulin-dependent diabetes [3] - The company's strategy focuses on high-volume automated manufacturing in the US and Malaysia, along with contract manufacturing in China [3]